| Abstract |
: |
Inspiring from the hybridization approach, a hybrid 6-(((5-(1-methoxy-9H-carbazol-3-yl)-1,3,4-oxadiazol-2-yl)amino)methyl)pyrimidine-2,4(1H,3H)-dione (3) was rationally designed and fabricated by incorporating murrayanine, 1,3,4-oxadiazole, and uracil components and screened for the exploration of the amplified anti-inflammatory potential by utilizing the carrageenan-induced paw edema method. The fabricated novel hybrid displayed significant edema reducing potential in the carrageenan-induced paw edema model as evidenced by 24.33%, 40.57%, and 59.99% reduction in the inflammation in the three individual hrs. On comparing the anti-inflammatory data of the previously developed murrayanine-oxadiazole derivative, it was observed that a significant decrease in the edema in rats has occurred with the addition of the uracil moiety to the present scaffold. It might be predicted from the present research that the reduction in edema in the rats may be due to the inhibition of inflammatory mediators like cyclooxygenase-1/2 (COX-1/2) and lipoxygenase (LOX) (primarily) by interacting with the active sites through the carbonyl, methoxy, and amide groups. The study will open new avenues of research for the modern age researchers in the rational designing of hybrid molecules with significant anti-inflammatory activity. |
Copyright to ENGG Journals Publications
